Cardiac-enriched lncRNAs for Ischemic Heart Failure Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for diagnosing, monitoring, and predicting cardiac disorders, particularly for differentiating between ischemic and non-ischemic heart failure, and for assessing drug-induced cardiac toxicities, which are critical for personalized and aggressive treatment approaches.
Innovation Solution
Identification and characterization of cardiac-enriched long non-coding RNAs (lncRNAs) for use as biomarkers in diagnosing and monitoring cardiac disorders, including heart failure, through deep RNA-sequencing and novel transcript reconstruction, enabling the development of methods for predicting cardiac events and evaluating treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarkers are used for diagnosing cardiac disorders, then the diagnostic process is simple and well-established, but the ability to differentiate between ischemic and non-ischemic heart failure is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by identifying specific lncRNA molecules (NOC L133729, NOC L23749, NOC L19889, ANX5A) that can be individually measured to differentiate between ischemic and non-ischemic heart failure. Each lncRNA serves as a distinct diagnostic marker that divides the diagnostic space into more precise categories.
Solution Approach 2:
The patent introduces lncRNAs as intermediary biomarkers that bridge the gap between conventional biomarkers and the need for precise differentiation. These lncRNAs act as mediators that provide additional diagnostic information without requiring complete overhaul of existing diagnostic systems.
2Reliability
If comprehensive cardiac monitoring is implemented to predict heart failure and assess drug toxicity, then the reliability of cardiac assessment is improved, but the cost and complexity of monitoring increases
Solution Approach 1:
The patent makes lncRNA biomarkers universal by demonstrating their applicability across multiple cardiac conditions including heart failure prediction, drug-induced toxicity assessment, and differentiation of ischemic versus non-ischemic etiologies. A single set of lncRNA markers serves multiple diagnostic functions.
Solution Approach 2:
The patent changes the diagnostic parameter from conventional biomarkers to lncRNA expression levels. This parameter change enables more reliable cardiac assessment across different conditions while using standardized molecular biology techniques for measurement.
3Manufacturing precision
If personalized treatment strategies are developed based on detailed cardiac pathology assessment, then treatment efficacy is improved, but the time and resources required for assessment increase
Solution Approach 1:
The patent performs preliminary assessment by measuring lncRNA expression levels early in the diagnostic process to predict heart failure risk and identify specific pathology types before treatment begins. This preliminary information allows for immediate personalization of treatment strategies without delaying care.
Data Source
AI summary
The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.